Minimal relapse risk and early normalization of survival for patients with Burkitt lymphoma treated with intensive immunochemotherapy: an international study of 264 real‐world patients

• DOI: 10.1111/bjh.16425
• Publication Date: 2020-02-04T11:05:20Z
• Authors: Lasse H. Jakobsen; Fredrik Ellin; Knut B. Smeland; Tove Wästerlid; Jacob H. Christensen; Judit M. Jørgensen; Pär L. Josefsson; Andreas K. Øvlisen; Harald Holte; Yngvild N. Blaker; Jacob H. Grauslund; Jon Bjørn; Daniel Molin; Ingemar Lagerlöf; Karin E. Smedby; Katherine Colvin; Gita Thanarajasingam; Matthew J. Maurer; Thomas M. Habermann; Kevin W. Song; Katie Y. Zhu; Alina S. Gerrie; Chan Y. Cheah; Tarec C. El‐Galaly
• Keywords: Adult; Aged, 80 and over; Male; Adolescent; 610; Burkitt lymphoma; Middle Aged; survival; Burkitt Lymphoma; Survival Analysis; real-world patients; 3. Good health; immunochemotherapy; Young Adult; 03 medical and health sciences; Treatment Outcome; 0302 clinical medicine; Humans; Female; prognosis; Aged; Retrospective Studies

Summary Non‐endemic Burkitt lymphoma (BL) is a rare germinal centre B‐cell‐derived malignancy with the genetic hallmark of MYC gene translocation and rapid tumour growth as distinct clinical feature. To investigate treatment outcomes, loss lifetime relapse risk in adult BL patients treated intensive immunochemotherapy, retrospective clinic‐based population‐based registries from six countries were used to identify 264 real‐world patients. The median age was 47 years majority had advanced‐stage disease elevated LDH. Treatment protocols R‐CODOX‐M/IVAC (47%), R‐hyper‐CVAD (16%), DA‐EPOCH‐R (11%), R‐BFM/GMALL (25%) other (2%) leading an overall response rate 89%. two‐year survival event‐free 84% 80% respectively. For complete remission/unconfirmed, 6% but diminished 0·6% for reaching 12 months post‐remission (pEFS12). pEFS12 0·4 (95% CI: −0·7 2) months. In conclusion, outcomes are excellent following immunochemotherapy. patients, low life expectancy similar that general population, which important information developing meaningful follow‐up strategies increased focus on survivorship less routine surveillance.